SOLO LAB / ANALYTICAL DOCUMENTATION
HPLC vs. Mass Spectrometry in Peptide Lab Reports
A chromatogram and a mass spectrum show different views of a sample. Reading them together starts with understanding the measurement, the method, and the question the laboratory actually investigated. If a laboratory later corrects a report, use the report revision checklist to track which version is current.
What is the difference between HPLC, MS, and LC-MS?
| Method | What to look for | Important limit |
|---|---|---|
| HPLC with UV detection | A separation over time, UV detector settings, and integrated peak areas. | A UV area percentage is a method-dependent response ratio, not automatically a mass percentage. |
| Mass spectrometry (MS) | A spectrum of ion signals and their m/z values, with the laboratory’s interpretation. | A matching intact mass does not distinguish every possible structure. |
| Liquid chromatography–mass spectrometry (LC-MS) | A liquid separation linked to MS detection; identify which eluting component supplied the spectrum. | The label alone does not say whether the work included quantitative calibration or tandem-MS analysis. |
| Tandem mass spectrometry (MS/MS) | Information from selected precursor and product ions, interpreted for the stated analytical purpose. | The useful structural information depends on the experiment and interpretation, not just the acronym. |
The IUPAC definitions of chromatography, LC-MS, and MS/MS describe the separation and measurement principles. These techniques can serve more than one purpose. It would be too simple to say that HPLC can only measure purity or that MS can only address identity.
How do you read an HPLC chromatogram?
Start with the axes. In a typical time-based chromatogram, the horizontal axis is retention time and the vertical axis is the recorded detector response. IUPAC’s chromatogram definition also allows other presentations, including response against effluent volume. Read the labels rather than assuming every plot uses the same units.
For a UV chromatogram, check the detection wavelength, the assigned principal peak, and the integration table. Ask which peaks were included in the area calculation. An unlabeled image or a headline percentage leaves those details unresolved.
Components may elute together, a problem called co-elution. A single visible peak therefore need not represent only one substance. In WHO good chromatography practices, sections 12–13, separation and documented integration are central to interpreting results, including unresolved peaks. The laboratory should explain atypical or manually integrated results.
Retention time also belongs to the stated chromatographic conditions. A time printed on one seller’s report is not a universal identifier you can transfer to a different method. For area-percentage interpretation, continue with purity, content, and concentration.
How is a mass spectrum different?
A mass spectrum arranges ion signals by mass-to-charge ratio, written m/z, rather than chromatographic time. The vertical axis commonly describes signal intensity or relative abundance. An m/z label and a reported molecular mass are different entries; the laboratory must identify the ion assignment and explain any conversion or processing.
Use the IUPAC mass-spectrum definition as a starting point. On the actual report, locate the expected and observed result, the assigned charge state, and the comparison criterion. Do not decide that a result matches simply because two rounded numbers look similar.
When the method is LC-MS, ask whether the displayed spectrum was taken from the relevant chromatographic peak. A chromatogram and a spectrum bearing the same compound name should still be connected to the same sample and report identifiers.
Does a matching molecular mass prove the complete peptide structure?
No. Different isomeric structures can share an exact mass. An intact-mass comparison can support an identity assessment without resolving every sequence or stereochemical possibility.
In a 2023 analytical study, Wu and colleagues investigated peptide isomers using fragmentation data and statistical comparison of spectra. Their work illustrates both the limitations of intact mass and the additional information specialized MS/MS analysis can provide. It does not mean that every routine MS report includes that analysis or that all isomers are impossible to distinguish.
FDA-published ICH Q6A, section 3.2.1(b), also explains why a single chromatographic retention time is insufficiently specific for identification and discusses combinations of analytical techniques. This pharmaceutical guidance informs the analytical distinction; it is not an approval or certification of a Solo Lab product.
What can you conclude when a COA lists both HPLC and MS?
ICH Q2(R2), section 3.1, emphasizes fitness for the intended analytical purpose and discrimination from interfering material. It discusses combining procedures where one provides insufficient selectivity. Two method names are useful context, but their supporting data determine the strength of the conclusion.
Separate the analytical questions when you take notes. Write down what each test measured and leave missing results marked as unreported. Do not fill those gaps from a catalog description, another batch, or a study about the molecule.
What should you ask when a report is unclear?
- Which product, lot, and laboratory sample does each chromatogram or spectrum describe?
- What detector and reporting basis were used for the HPLC result?
- Which peak was assigned to the target, and how were overlapping peaks handled?
- Does the MS entry report an intact-mass comparison, MS/MS interpretation, or another specific test?
- What reference, acceptance criterion, and interference assessment supported identification?
- Can the issuer provide the applicable supporting output and explain any missing information?
You do not need to reconstruct a laboratory procedure to ask a useful question. Identify the missing field, the report identifier, and the conclusion you are trying to understand.
Review the original record
Find the applicable published Lab Results, then use the COA reading checklist to match the sample and batch. If the method or supporting result is unclear, ask Solo Lab about that specific document.
The Peptide Guide explains compound research context. This article explains analytical documentation; it does not claim any particular test was performed on a Solo Lab item or provide personal-use instructions.
Sources and scope
Sources reviewed October 27, 2026. Official guidance is cited for analytical principles in its original pharmaceutical context. The experimental paper concerns analytical characterization, not a treatment study or a Solo Lab batch.
- IUPAC: chromatography and chromatogram.
- IUPAC: mass spectrum, LC-MS, and tandem mass spectrometry.
- WHO TRS 1025, Annex 4 (2020), sections 12–13: chromatographic methods and integration.
- FDA / ICH Q6A, section 3.2.1(b): specificity of identification procedures.
- FDA / ICH Q2(R2), March 2024, section 3.1: specificity, selectivity, and complementary procedures.
- Wu, Riggs, Lyon, and Julian (2023), Analytical Chemistry, 95, 6996–7005: Statistical Framework for Identifying Differences in Similar Mass Spectra: Expanding Possibilities for Isomer Identification. DOI.
